Findings reveal chemotherapy impairs sperm quality in testicular cancer, suggesting personalized fertility preservation strategies.
Sperm quality in TGCT patients showed marked variability. Non-seminoma diagnosis appeared less detrimental than seminoma, yet BEP chemotherapy severely impaired sperm parameters, especially in non-seminoma cases. These results highlight the importance of individualized post-chemotherapy monitoring using standard semen analysis, cytometry-based qualitative assessments, and epigenetic profiling of histone modifications to optimize fertility preservation and guide optimal treatment strategies by andrologists.
No takes yet. Share an insight, caveat, or question.
Sanovec et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: